Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD.
Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as well as an impressive resume of business development expertise.
“This is a very exciting addition to the CPDC team,” stated Dr. Joe McCann, CEO of CPDC. “Bruno will lead the growth of our radiopharmaceutical imaging products business as well as provide business support to our contract services unit that is focused on regulatory affairs and clinical trial management. With Bruno’s knowledge and expertise, he will play a key role in keeping CPDC at the forefront of the industry.”
Bruno received his PhD in Biochemistry from Université de Montréal before conducting his post-doctoral research at the University of Albany. He became the Laboratory Director at Université de Montréal, Département de Biochimie, where he was responsible for the management and direction of a team of scientists. In 2000, he became the head of the Technology Development Unit at Genizon Biosciences Inc., where he was appointed the Executive Director, Head of Business Development.
In 2010, Bruno became a consultant for Business & Strategy Development in Life Sciences, Genetics and Pharmacogenomics for several organizations, and then went on to become VP of Business Development for Immuni T in Montréal in 2011. He has published extensively, is a named inventor in over 24 patent applications and has presented at international conferences.
Dr. Paquin stated, “I’m proud to become part of such an impressive organization that plays a major role in helping Canadians. I look forward to working alongside Dr. McCann and the rest of the team to extend the reach of CPDC products and services.”
The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.
Centre for Probe Development and Commercialization
Angela Laurentani, 905 525-9140, ext. 21212
Hamilton, Ontario, October 3, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, today is announcing that its founder, Dr. John Valliant, has stepped down from his role as CEO to focus his time as the CEO of Fusion Pharmaceuticals. Dr. Valliant will
HAMILTON, Ontario, September 13, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, and the McMaster Nuclear Reactor facility (MNR), a leading research reactor program that provides a source of medical radioisotopes, announced today that they have signed an agreement to explore the
LOS ANGELES, August 29, 2018 – ImaginAb Inc, an immuno-oncology imaging company, and Centre for Probe Development and Commercialization (CPDC), a Canadian centre of excellence specializing in radiopharmaceutical development and cGMP manufacturing, today announced that they have entered into a development and manufacturing agreement for the supply of ImaginAb’s clinical-phase Positron Emission Tomography (PET) imaging